Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 41,803 shares of the specialty pharmaceutical company's stock after selling 3,026 shares during the quarter. Wellington Management Group LLP owned approximately 0.07% of Jazz Pharmaceuticals worth $5,148,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Barclays PLC increased its holdings in Jazz Pharmaceuticals by 19.1% during the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after purchasing an additional 6,289 shares during the period. Blue Trust Inc. grew its position in shares of Jazz Pharmaceuticals by 83.7% during the 4th quarter. Blue Trust Inc. now owns 1,868 shares of the specialty pharmaceutical company's stock worth $230,000 after buying an additional 851 shares in the last quarter. Caprock Group LLC purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $206,000. Trust Point Inc. purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at $213,000. Finally, Tectonic Advisors LLC raised its holdings in shares of Jazz Pharmaceuticals by 12.4% in the fourth quarter. Tectonic Advisors LLC now owns 4,374 shares of the specialty pharmaceutical company's stock valued at $539,000 after acquiring an additional 483 shares in the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on JAZZ shares. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their target price for the company from $145.00 to $179.00 in a research report on Friday, March 7th. JPMorgan Chase & Co. upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. HC Wainwright upped their target price on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a "buy" rating in a research report on Thursday, March 6th. Finally, Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $182.93.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan purchased 100,000 shares of the business's stock in a transaction that occurred on Friday, May 9th. The shares were bought at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the acquisition, the director now owns 100,000 shares in the company, valued at $9,826,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CMO Robert Iannone sold 7,080 shares of the company's stock in a transaction on Friday, March 7th. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00. Following the completion of the sale, the chief marketing officer now directly owns 82,024 shares in the company, valued at $11,368,526.40. This trade represents a 7.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,623 shares of company stock worth $1,826,916. Company insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Stock Down 0.6%

NASDAQ:JAZZ traded down $0.65 during mid-day trading on Thursday, hitting $108.80. 637,538 shares of the company's stock traded hands, compared to its average volume of 837,841. The company has a fifty day moving average of $108.68 and a 200 day moving average of $121.10. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The company has a market capitalization of $6.71 billion, a P/E ratio of 15.32, a P/E/G ratio of 1.04 and a beta of 0.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The business's revenue was down .5% compared to the same quarter last year. During the same quarter last year, the company earned $2.68 EPS. On average, analysts forecast that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.